Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today reported cash and cash equivalents of €5.6 million as of March 31, 2020. This amount does not include the French research tax credit of €0.9 million which was received by the Company in April 2020. The existing cash and cash equivalents provide cash runway to end of February 2021. 

COVID-19 update In the context of the COVID-19 pandemic, the Company is following applicable guidelines and recommendations in order to protect its employees and contractors. The Company has also implemented strategies to mitigate the impact of the global shutdown on its business and operations.

The Company has asked its employees in France and Switzerland to work from home and to organize meetings and events virtually as much as possible.

To date, the Company is only anticipating a limited impact on its operations, including the planned discussions with regulatory authorities, the conducting of clinical trials as well as interactions with the scientific community and other stakeholders. The Company will continue to monitor the possible impact of COVID-19 on the conducting of clinical trials and discussions with health authorities and, depending on the evolution of the pandemics and of its material impact on such trials and discussions, will report to the markets on any such material impact.

The Company has made progress in its key activities, in particular the end-of-phase-2 discussions with regulators with a view to a phase 3 study in Primary biliary cholangitis (PBC), and the conducting of the phase 1 study with setanaxib as described in the clinical highlights section below. The launch of the phase 2 trial in IPF is still expected in 2020 and could occur in the first semester despite the COVID-19 situation.

Download full press release